CRDL (Cardiol Therapeutics) Total Equity: $17.64 Mil (As of Mar. 2026)


CRDL Cardiol Therapeutics Inc CRDL
34 GF Score
Price $1.05
! 3 Warning Signs
View Full Analysis

What is Cardiol Therapeutics Total Equity?

Cardiol Therapeutics CRDL 34 Total Equity is $17.64 Mil as of Mar. 2026. GuruFocus rates CRDL with a GF Score™ of 34/100. The stock has 3 warning signs investors should review.

Cardiol Therapeutics's total equity for the quarter that ended in Mar. 2026 was $17.64 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Cardiol Therapeutics Total Equity Historical Data

* Premium members only.

The historical data trend for Cardiol Therapeutics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardiol Therapeutics Total Equity Chart

Cardiol Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only 59.56 38.43 21.06 17.36 12.96

Cardiol Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.25 8.64 6.91 12.96 17.64
CRDL
34GF Score
Cardiol Therapeutics Inc CRDL
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cardiol Therapeutics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Cardiol Therapeutics's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=17.122-4.162
=12.96

Cardiol Therapeutics's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=22.891-5.25
=17.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $17.64 Mil mean?
Cardiol Therapeutics (CRDL) has a Total Equity of $17.64 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Cardiol Therapeutics and its competitors.
Is Cardiol Therapeutics' Total Equity too high?
Cardiol Therapeutics' current Total Equity is $17.64 Mil. Overall, Cardiol Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Cardiol Therapeutics' Total Equity compare to ZTS and UTHR?
Cardiol Therapeutics' Total Equity of $17.64 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Cardiol Therapeutics and its competitors. Cardiol Therapeutics's current Total Equity is $17.64 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiol Therapeutics stock overvalued right now?
Cardiol Therapeutics (CRDL) has a current Total Equity of $17.64 Mil. The current Total Equity is $17.64 Mil. Cardiol Therapeutics' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Cardiol Therapeutics (CRDL), the current Total Equity is $17.64 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cardiol Therapeutics Business Description

Other Exchanges CT9:GermanyCRDL:Canada
Address 2265 Upper Middle Road East, Suite 602, Oakville, ON, CAN, L6H 0G5
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
34GF Score

Get the complete analysis for CRDL

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.05
Price